US Edition
News from Cambridge Times
We’ve assigned a media bias rating of Lean Left to Cambridge Times. You can read more about our methodology here.
Information about Cambridge Times
Where is Cambridge Times located?Cambridge, CanadaCambridge Times's WebsiteCambridge Times's TwitterCambridge Times's WikipediaMedia Bias Ratings
Average Bias Rating:
Lean Left
Lean Left
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Cambridge Times News
Tokyo, Japan · TokyoTOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions…See the Story
LEQEMBI® IQLIK™(lecanemab-Irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Biogen (NASDAQ:BIIB)
54% Center coverage: 22 sources
